Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
  • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
  • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/02—Boron compounds
  • C07F5/022—Boron compounds without C-boron linkages
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/06—Aluminium compounds
  • C07F5/069—Aluminium compounds without C-aluminium linkages
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/025—Silicon compounds without C-silicon linkages
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B47/00—Porphines; Azaporphines
  • C09B47/04—Phthalocyanines abbreviation: Pc
  • C09B47/045—Special non-pigmentary uses, e.g. catalyst, photosensitisers of phthalocyanine dyes or pigments
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B47/00—Porphines; Azaporphines
  • C09B47/04—Phthalocyanines abbreviation: Pc
  • C09B47/06—Preparation from carboxylic acids or derivatives thereof, e.g. anhydrides, amides, mononitriles, phthalimide, o-cyanobenzamide
  • C09B47/067—Preparation from carboxylic acids or derivatives thereof, e.g. anhydrides, amides, mononitriles, phthalimide, o-cyanobenzamide from phthalodinitriles naphthalenedinitriles, aromatic dinitriles prepared in situ, hydrogenated phthalodinitrile
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B47/00—Porphines; Azaporphines
  • C09B47/04—Phthalocyanines abbreviation: Pc
  • C09B47/08—Preparation from other phthalocyanine compounds, e.g. cobaltphthalocyanineamine complex
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

• the present invention relates to metal-phthalocyanines bearing at least one group containing boron isotopes 11 B or 10 B covalently bound to the peripheral positions of the metal-phthalocyanine nucleus; moreover it refers to the processes for their preparation, the pharmaceutical compositions comprising them and their use for the treatment of neoplastic and dysplastic pathologies. STATE OF THE ART
• ROS reactive oxygen species
• the derivatives described in the above cited patents and patent applications combine high quantum yields of singlet oxygen production, high absorptions in the red region of visible spectrum and optimum solubility in aqueous medium or formulations, suitable for topical administrations.
• the side chains, from one side provide the physical-chemical features required for the photosensitising efficiency, from the other guarantee the high bio-availability of the products, the fast metabolism of the derivatives and thus the final clearance for an optimal localization of the active molecules in the target, thus limiting their toxicity.
• BNCT Boron Neutron Capture Therapy
• novel boronated metal- phthalocyanines bearing up to eight peripheral substituents containing boron isotopes 10 B, may be used as products for both BNCT and PDT. These products are able to carry amounts of boron greater than the minimum dose needed for the success of BNCT treatment into the tumour cells, while still showing a high photodynamic efficiency and a selective uptake in rapidly proliferating cells.
• This finding was unexpected on the light of the previously cited literature and know- how, where good uptake and localizing properties as well as optimal photodynamic characteristics were found for phthalocyanine derivatives having only one boron cluster substituent (undecahydro- closo- dodecaboromercaptocarbonylphenoxy).
• Subject of the present invention are therefore compounds of general formula (I)
• Me is chosen in the group consisting of Zn, AIOR 4 and Si(OR 4 ), wherein R 4 is chosen in the group consisting of H and C1-C15 alkyl, R, Ri, R2 and R 3 , equal or different from one other, are selected from H and groups (G) s -(X)r(Y-Z) u wherein:
• G is selected from the group consisting of O, S, SO, CH 2 and N;
• X is selected from the group consisting of phenyl, linear or branched C1-C10 alkyl,
• Y is selected from the group consisting of S, (CH 2 ) n , phenyl, 0-(CH 2 ) n , (CH 2 ) n -0-,
• Z is selected from the group consisting of 11 B-(o,m,p-carborane), 11 B- undecahydrododecaboromercaptyl, 11 B-undecahydrododecaborate, 10 B-(o,m,p- carborane), 10 B-undecahydrododecaboromercaptyl and 10 B- undecahydrododecaborate; n is an integer comprised between 1 and 10;
• Fig. 1 Photooxydation kinetics of 9,10-dimethylantracene (DMA) with tetrasubstituted boronated phhalocyanine prepared as described in Example 21 in DMF, after irradiation with 600-700 nm light at 100 mW/cm 2 .
• Fig. 2A Absorption spectrum and determination of the degraded unsubstituted zinc phthalocyanine, irradiated according to the experimental conditions described above for Fig. 1.
• Fig. 2B Absorption spectrum and determination of degraded boronated phthalocyanine, prepared according the Example 21, irradiated according to the experimental conditions described in Fig. 1.
• Fig. 3 Percentage survival of transformed B16F1 murine melanocites as a function of the irradiation time after 24 hours incubation with boronated phthalocyanine prepared according to Example 21, as a DL ⁇ -dipalmitoyl phosphatidylcoline (DPPC) liposomal preparation (3A) or a DOPC liposomal preparation (3B). Irradiations were performed as described above for Fig.1.
• Fig. 3 Percentage survival of transformed B16F1 murine melanocites as a function of the irradiation time after 24 hours incubation with boronated phthalocyanine prepared according to Example 21, as a DL ⁇ -dipalmitoyl phosphatidylcoline (DPPC) liposomal preparation (3A) or
• B Pc boronated phthalocyanine
• boronated phthalocyanine 0.75 mg/Kg of boronated phthalocyanine according to Example 21 as DPPC liposomal preparation.
• Fig. 5 Time-dependence of boronated phthalocyanine (B 4 PC) recovery from plasma and selected tissues of B16-F1 pigmented melanoma bearing C57/BL6 mice (5A), as well as from tumour and skin (5B) after iv administration of 3.0 mg/Kg of boronated phthalocyanine according to Example 21 as DOPC liposomal preparation.
• Fig. 6 Rate of tumour growth as a function of post-irradiation time in C57/BL6 mice bearing a B16F1 transplanted pigmented melanoma which have been intravenously injected with 6.0 mg/kg boronated phthalocyanine prepared according to Example 21 as a DOPC liposomal preparation and then irradiated by red visible light (670 nm from a diode laser) at a fluence-rate of 200 mW/cm 2 and a total light dose of 250 J/cm 2 .
• red visible light 670 nm from a diode laser
• the present invention allows one to meet the above-mentioned requirements thanks to the compounds of formula (I) as above described.
• the Applicant has surprisingly found that the products subject of the present invention maintain the physical-chemical properties linked with the photosensitising features, particularly the wavelength, the fluorescence and quantum yield of singlet-oxygen production and the molar extinction coefficient. These products are also able to efficiently localize into tumours after systemic administration as well and can efficiently sensitize a hard-tortreat tumour, such as the pigmented melanoma, to both PDT and BNCT.
• the presence of at least one substituent bearing at least two or more 11 B or 10 B isotopes clusters on the peripheral position of the macrocycle, neither interferes with cellular localization estimated on model cells, nor with the photobleaching processes, while it provides optimal characteristics.
• Cells may thus be inactivated through a photodynamic mechanism related to the phtahlocyanine and is also possible to inactivate tumour cells by means of BNCT, due to the presence of a sufficiently large number of boron atoms on the phthalocyanine carrier, as well as to the sufficiently high affinity of the boronated phthalocyanine for an experimental tumour model.
• Preferred compounds according to the present invention are the compounds of formula (I) in which Me is Zn.
• the present compounds of formula (I) may carry from one to eight groups bearing 11 B or 10 B isotopes in the alpha or beta positions on the phthalocyanine molecule, preferably at the positions 1 (4),8(11 ),15(18),22(25) or 2(3),9(10), 16(17),23(24).
• G is O
• X is phenyl
• Y is CH 2 .
• the compounds of the present invention can be prepared according to reaction schemes known in organic chemistry, for example by using one of the following general procedures: a) process comprising the tetramerization of the functionalised phthalonitriles of general formula (II)
• T is a group (G) s -(X) r (Y-Z)u wherein G, X, Y, Z, s, t, and u are as defined above; and r is 1 , 2; alone or in the presence of dicyanobenzene, possibly in the presence of a reaciant suitable for introducing the metal into the phthalocyanine nucleus, thus obtaining a compound of formula (I).
• Scheme 1 the tetramerization of compound (II), alone or with dicyanobenzene, in the presence of Zn(OAc)a is illustrated.
• T and r are as defined above, and W is selected from the group consisting of N0 2 , NH 2) Cl, Br, I, OH, and (G) s -(X)r(P) u , wherein G, X, s, t and u are as defined above, and P is selected from the group consisting of Br, Cl, I, C ⁇ CH, CHO, COOH, NH 2 , OH, methansulfonyloxy, tosyloxy and Y, wherein Y is as defined above.
• N-bromosuccinimide (790 mg, 4.4 mmol) was dissolved in dichloroethane and the mixture was warmed to reflux.
• 3-[3,5-bis-(methyl)phenoxy]phthalonitrile 500 mg, 2 mmol), prepared according to procedures described in literature, and a catalytic amount of benzoyl peroxide were added and the mixture was refluxed for 1.15 hours.
• the reaction mixture was diluted with dichloromethane, washed with saturated solution of NaHC0 3 and water and dried on Na 2 S0 4 .
• Singlet oxygen is produced through an electron energy transfer from the phthalocyanines in their excited triplet state to molecular oxygen.
• it represents the main phototoxic intermediate in the photosensitising processes.
• the boron substituted molecules prepared according to the present invention are as useful photosensitizers able to absorb red visible light as the unsubstituted ones;
• the photobleaching kinetics undergoes only limited changes when the phthalocyanine structure is modified by introduction of boronated groups. Indeed, the more extensive photobleaching found for the boronated compound has the advantage to induce an easier elimination of excess drug, thereby avoiding the onset of delayed photosensitization, obviously compared to its control represented by a not-boronated compound.
• Example 21 The tetra-substituted boronated phthalocyanine prepared as described in Example 21 has been used for the photosensitization of melanocytes deriving from murine pigmented melanoma B16-F1.
• Melanocytes were incubated (24 hrs) with a DPCC or DOPC liposomal phthalocyanine preparation (7 microM). After incubation, the cells were washed with PBS and irradiated with red visible light (600-750 nm, 50 mW/cm 2 ). Survival was determined after the photo-treatment (18-24 hrs) by the Trypan Blue exclusion test.
• the boronated phthalocyanine is able to induce a significant delay in the rate of tumour growth, when the mice bearing a subcutaneously transplanted pigmented melanoma are exposed to red light. The tumour response is most evident if the irradiations are carried out at 3 h after injection of the photosensitizer.
• the tetra-substituted phthalocyanine, reported in Example 21 is accumulated in large amounts, both in the liver and in the spleen, and, at least the phthalocyanine delivered via DOPC liposomes, is largely cleared from liver and spleen after 1 week from injection. This would indicate that no persistent general photosensitivity can be expected beyond one week after the administration of the phthalocyanine. Very limited amounts of phthalocyanine are recovered from the kidneys, which suggests that the photosensitizer is cleared from the organism almost exclusively via the bile-gut pathway.
• the compounds of formula (I), reported in the present invention are therefore useful for treatment of tumours, pre-cancerous and hyperproliferative conditions, using a combined PDT/BNCT approach, further benefiting from their fluorescence emission properties, that allow the identification of the pathological areas before and during the therapeutic treatment.
• the products can be administered parenterally, by using pharmaceutical formulations known in the state of the art, and proceeding with the BNCT/PDT treatment, after localization has taken place.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=32983184

Family Applications (1)

Country Status (15)

Cited By (2)

Families Citing this family (5)

Citations (2)

Family Cites Families (1)

• 2003
  • 2003-03-11 IT IT000063A patent/ITFI20030063A1/it unknown
• 2004
  • 2004-03-11 US US10/548,793 patent/US7842682B2/en not_active Expired - Fee Related
  • 2004-03-11 WO PCT/EP2004/002505 patent/WO2004081014A1/en not_active Ceased
  • 2004-03-11 CA CA2518934A patent/CA2518934C/en not_active Expired - Fee Related
  • 2004-03-11 JP JP2006504641A patent/JP4968673B2/ja not_active Expired - Fee Related
  • 2004-03-11 ES ES04719429T patent/ES2311147T3/es not_active Expired - Lifetime
  • 2004-03-11 AT AT04719429T patent/ATE402936T1/de active
  • 2004-03-11 DE DE602004015428T patent/DE602004015428D1/de not_active Expired - Lifetime
  • 2004-03-11 DK DK04719429T patent/DK1603918T3/da active
  • 2004-03-11 AU AU2004220406A patent/AU2004220406B2/en not_active Ceased
  • 2004-03-11 CN CNB2004800065335A patent/CN100374442C/zh not_active Expired - Fee Related
  • 2004-03-11 PL PL04719429T patent/PL1603918T3/pl unknown
  • 2004-03-11 EP EP04719429A patent/EP1603918B1/en not_active Expired - Lifetime
• 2005
  • 2005-09-08 IL IL170761A patent/IL170761A/en not_active IP Right Cessation
  • 2005-10-03 ZA ZA200507975A patent/ZA200507975B/en unknown

Patent Citations (2)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events